Table 1.
Correlations between BDNF or sprouty2 mRNA levels and confounding variables
Table 2.
Effect of antipsychotic treatment on BDNF and sprouty2 mRNA expression
Figure 1.
Normalized Sprouty2 mRNA expression in schizophrenia, bipolar and control subjects.
Values are expressed as mean±SEM. The number of individuals per sample is indicated within each bar. Sprouty2 expression is significantly low in schizophrenia and bipolar subjects as compared to control subjects. Level of significance as compared to control subjects is shown above each bar.
Table 3.
Correlation between BDNF and sprouty2 mRNA levels
Figure 2.
Normalized BDNF mRNA expression in schizophrenia, bipolar and control subjects.
Values are expressed as mean±SEM. The number of individuals per sample is indicated within each bar. BDNF expression is significantly low in schizophrenia and bipolar subjects as compared to control subjects. Level of significance as compared to control subjects is shown above each bar.
Figure 3.
BDNF and Sprouty2 expression in the frontal cortex of rats treated with haloperidol or olanzapine.
Adult rats were treated with haloperidol (2 mg/kg) or olanzapine (10 mg/kg) through drinking water for 45 days, and (A) protein and (B) mRNA levels of BDNF and Sprouty2 in frontal cortex were estimated after the treatment. BDNF protein levels were measured by ELISA and Sprouty2 proteins levels were estimated by Western blot analysis. mRNA levels of both BDNF and Sprouty2 were estimated by qRT-PCR analysis. Open bars represent haloperidol-treated rats whereas filled bars represent olanzapine-treated rats. Values are expressed as fold change relative to vehicle-treated rats. *p<0.05, n = 10–12 per group.
Table 4.
Demographic data for post mortem brain samples.
Table 5.
List of primer sequences used for postmortem studies.